|
21 Sep 2023 |
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
|
|
21 Sep 2023 |
Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR-T Cell Therapy LEU011
|
|
21 Sep 2023 |
Fresenius Kabi’s biosimilar Tyenne®* becomes first tocilizumab biosimilar approved by the European Commission
|
|
21 Sep 2023 |
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers
|
|
20 Sep 2023 |
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
|
|
20 Sep 2023 |
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
|
|
20 Sep 2023 |
Hepagene Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for HPG7233 THR Beta Agonist
|
|
20 Sep 2023 |
Sapience Therapeutics Announces Presentation of ST101 Clinical Data at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
|
|
20 Sep 2023 |
SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01
|
|
20 Sep 2023 |
RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers Including Brain, Pancreatic and Liver
|
|
20 Sep 2023 |
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
|
|
20 Sep 2023 |
European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
|
|
20 Sep 2023 |
Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines
|
|
20 Sep 2023 |
PeptiDream Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide-Radioisotope Drug Conjugates
|
|
20 Sep 2023 |
Merck KGaA, Darmstadt, Germany, Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
|
|
19 Sep 2023 |
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
|
|
19 Sep 2023 |
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
|
|
19 Sep 2023 |
LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis
|
|
19 Sep 2023 |
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
|
|
19 Sep 2023 |
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
|
